Alvesco 80 mikrog/annos inhalaatiosumute, liuos Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

alvesco 80 mikrog/annos inhalaatiosumute, liuos

covis pharma europe b.v. - ciclesonide - inhalaatiosumute, liuos - 80 mikrog/annos - siklesonidi

Alvesco 160 mikrog/annos inhalaatiosumute, liuos Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

alvesco 160 mikrog/annos inhalaatiosumute, liuos

covis pharma europe b.v. - ciclesonide - inhalaatiosumute, liuos - 160 mikrog/annos - siklesonidi

Eklira Genuair Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

eklira genuair

covis pharma europe b.v. - aclidinium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - eklira genuair ilmoitetaan huolto keuhkoputkia hoito lievittää oireita aikuispotilailla, joilla on krooninen keuhkoahtaumatauti (copd).

Brimica Genuair Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

brimica genuair

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - brimica genuair on tarkoitettu huolto keuhkoputkia hoito ilmavirran tukkeuma ja oireiden lievittämiseen aikuisilla potilailla, joilla on krooninen keuhkoahtaumatauti (copd).

Duaklir Genuair Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

duaklir genuair

covis pharma europe b.v. - aclidinium bromidi, formoteroli fumarate dihydraatti - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - duaklir genuair on tarkoitettu ylläpitämään bronkodilataattorikäsittelyä oireiden lievittämiseksi aikuispotilailla, joilla on krooninen obstruktiivinen keuhkosairaus (copd).

Bretaris Genuair Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

bretaris genuair

covis pharma europe b.v. - aclidinium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - bretaris genuair on tarkoitettu ylläpitohoidon bronkodilataattorikäsittelyksi oireiden lievittämiseksi aikuispotilailla, joilla on krooninen obstruktiivinen keuhkosairaus (copd).

Fencovis RCE vet injektioneste, suspensio Finlanda - finlandeză - Fimea (Suomen lääkevirasto)

fencovis rce vet injektioneste, suspensio

boehringer ingelheim vetmedica gmbh - inactivated bovine rotavirus, strain tm-91 , inactivated bovine coronavirus, strain c-197, escherichia coli f5 (k99) adhesin - injektioneste, suspensio

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - rokotteet - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - rokotteet - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Spikevax (previously COVID-19 Vaccine Moderna) Uniunea Europeană - finlandeză - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.